Muhammad O Awiwi,1 Khaled M Elsayes,1 Yehia I Mohamed,2 Lina Altameemi,2 Migena Gjoni,3 Omayr Muhammad Irshad,4 Ahmed Sayed Ahmed,5 Ahmad O Kaseb,2 Usama Salem1 1Department of Diagnostic Imaging, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; 2Department of Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; 3Department of Internal Medicine, The of Istanbul-Cerrahpasa Hospital, Istanbul, Turkey; 4John Sealy School of Medicine, Galveston, TX, USA; 5Department of Gastroenterology, The University of Texas MD Anderson Cancer Center, Houston, TX, USACorrespondence: Khaled M Elsayes, 1515 Holcombe Blvd, Houston, TX, 77030, USA, Tel +1 877 632-6789, Fax +1 713 794-4535, Email KMElsayes@mdanderson.orgPurpose: To identify prognostic clinical and radiologic features in patients with unresectable hepatocellular carcinoma (HCC) treated with atezolizumab plus bevacizumab.Patients and Methods: Clinical and imaging records of patients with unresectable HCC were retrospectively reviewed, and baseline features were recorded. Patientsâ records and imaging studies were used to determine the patientsâ overall survival (OS) and progression-free survival (PFS). Univariate and multivariate analyses were performed to determine prognostic features. Subanalyses of treatment-naïve patients (who never received local or systemic therapy) and previously treated patients were also performed.Results: Fifty-five patients were included in the final analysis, 23 (41.8%) of whom were treatment naïve. The median PFS and OS for the entire cohort were 3.0 months and 7.9 months. The 3-, 6- and 12-month OS rates were 85.5%, 79.8% and 45.7%, respectively. The 3-, 6- and 12-month PFS rates were 50.1%, 41.2% and 20.1%, respectively. On multivariate analysis, independent prognostic features for poor PFS of the entire cohort were pleural effusions (p = 0.047, HR: 6.3; CI: 1.03â 38.90) and hepatic vein tumor thrombus (p = 0.005; HR: 23.37; CI: 2.63â 207.67); independent prognostic features for poor OS were ascites (p = 0.008; HR: 37.37; CI: 2.53â 467.64), pleural effusion (p = 0.003; HR: 110.17; CI: 5.00â 2426.54), and low (< 40HU) pre-contrast attenuation on CT images (p = 0.007; HR: 0.09; CI: 0.02â 0.53). On subanalysis of treatment-naïve patients, the median OS and PFS were 7.4 months and 2.8 months, respectively. The 3-, 6- and 12-month PFS rates were 43.5%, 38.6% and 24.8%, respectively. Pleural effusion was the only independent poor prognostic feature (p = 0.036; HR: 206.34; CI: 1.41â 30,167.58).Conclusion: Independent prognostic features for survival outcomes include the presence of ascites, pleural effusions, hepatic vein tumor thrombus, and HCC with low attenuation (< 40 HU) on unenhanced CT images. Although several biochemical variables were significant on univariate analysis, none were independent predictors of OS or PFS.Keywords: radiographic, radiology, RECIST, survival, neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio